Dr. Pollen K. Yeung, BSc Pharm, PhD
Professor, College of Pharmacy and Department of Medicine
Pharmacokinetics, Metabolism, Biomarkers, Cardiovascular Protection, Anti-cancer drugs
Although many anti-cancer drugs are highly effective against susceptible cancers in chemotherapy, they are often associated with serious cardiac adverse effects; and resistance to drug therapy may develop after prolonged treatment. It has been postulated that cardiac adverse effects may be reduced by combining them with drugs or natural health products for treatment of cardiovascular disease. Our research interest is to investigate whether or not combining these anti-cancer drugs with cardiovascular protective agents would improve pharmacokinetics and minimize their cardiovascular toxicities. This will lead to development of novel drug combinations of anti-cancer drugs for cancer chemotherapy, resulting in improved patient outcomes, longer survival and better quality of life.
Membership Status:Dr. Yeung is a BHCRI Associate Member and has served as a member of a BHCRI Scientific Review Committee.
Address:Pharmacokinetics and Metabolism Laboratory, College of Pharmacy, Dalhousie University, Halifax, NS, Canada B3H 4R2
Yeung, PKF, Purcell, C, Akhoundi, F, and Agu, RU. Adenosine and Adenosine 5’-triphosphate Catabolism in Systemic Blood as a Potential Biomarker for Doxorubicin Cardiotoxicity in an Experimental Rat Model in vivo. Cardiovascular & Haematological Disorders-Drug Targets 18(1) 1 – 10, 2018.
Yeung, PKF, Mohammadizadeh, SM and Akhoundi, F. Therapeutic potential of Resveratrol in Complementary Medicine for Chronic Disease Management (Editorial). Natural Product Chemistry and Research Open Access 5: e122, 2017.
Bartlett, JL, Trivedi, PC, Yeung, PKF, Kienesberger, PC, and Pulinilkunnil, T. Doxorubicin Impairs Cardiomyocyte Viability by Suppressing Transcription Factor EB Expression and Disrupting Lysosomal Autophagy. Biochemical Journal 473: 3769 – 3789, 2016.
Yeung,PKF, Tinkel, J and Seeto, D. A Pilot Study to Assess Adenosine 5’-triphosphate Metabolism in Red Blood Cells as a Drug Target for Potential Cardiovascular Protection. Cardiovascular& Hematological Disorders - Drug Targets, 15 (3): 224 – 232, 2016
Kolathuru SS and Yeung, PKF. Therapeutic Potential of Adenosine Transport Modulators for Cardiovascular Protection (Editorial). Cardiol Pharmacol 4:3 e127, 2015.
Tillman, P and Yeung, PKF. Coenzyme Q10 for cardiovascular prevention (Editorial). Cardiol Pharmacol 3: e125, 2014.
Yeung, PKF, Xu, Z and Seeto, D. Diltiazem Reduces Mortality and Breakdown of ATP in Red Blood Cell Induced by Isoproterenol in a Freely Moving Rat Model in Vivo Metabolites 4: 775 -789, 2014.
Yeung,PKF. ATP Metabolism as Biomarker Target for Cardiovascular Protection (Editorial). Cardiol Pharmacol 2:e118, 2013
Feridooni, T, MacDonald, C, Shao, Di, Yeung, PKF, Agu, RU Cardio-protective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9C2 cell line. Acta Pharmaceutica 63:493-503, 2013.
Starr, L, Purcell, C and Yeung, P.K. F. Effect of doxorubicin on cardiovascular hemodynamic and RBC concentrations of ATP in rats in vivo. Current Topics in Pharmacology 16:59-65, 2012.